Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer
Posted inGastroenterology news Oncology

Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer

The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with significantly improved outcomes, establishing a new standard for precision oncology.
Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity
Posted inGastroenterology news Oncology

Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity

Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and synergizes with PD-1 inhibitors to convert immunologically 'cold' tumors into 'hot' responsive environments.
Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial
Posted inHematology-Oncology news Oncology

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhanced antitumor efficacy and potential improvement in treatment adherence through hot flash mitigation.
More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Posted innews Oncology Urology

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
Posted innews Oncology

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminating the need for cyclophosphamide pretreatment.
Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial
Posted inHematology-Oncology news Oncology Psychiatry

Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial

A randomized clinical trial demonstrates that telehealth-delivered music therapy is noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors, providing durable, clinically meaningful improvements and a viable alternative to traditional psychological interventions.